7-marker protein test to predict NSCLC response to anti-PD-1 therapy
Official title: Analytic and Clinical Validation of a 7-plex MIF Assay for Predictive Response of Advanced NSCLC to Anti-PD-1 based Therapy
Funded at Johns Hopkins University · NIH-11552207 · Data updated 2026-11-12
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 16, 2022 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $314,097 |
| NIH project number | 4UH3CA272905-03 |
| Project ID | NIH-11552207 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with advanced NSCLC whose pretreatment tumor tissue is available for biomarker testing.
✕Less likely to help
Patients whose tumors do not express the relevant biomarker patterns or who are not treated with anti-PD-1 based therapy.
What this research studies
This project develops a multiplex immunofluorescence assay that measures PD-L1, PD-1, CD8, FoxP3, CD68, a tumor marker, and a membrane marker on pretreatment tumor tissue. It adds spatial and co-expression information to improve prediction of who will benefit from anti-PD-1 therapy beyond PD-L1 alone. The approach focuses on NSCLC and uses tissue samples to enumerate immune and tumor cell features that relate to treatment response. Researchers aim to show that these combined biomarkers more accurately forecast benefit than current scoring alone.
Why it matters
Potential benefit: If successful, the test could better identify NSCLC patients most likely to respond to anti-PD-1 therapy, potentially guiding treatment choices.
How similar studies have gone: Prior work shows PD-L1 alone is imperfect; combining multiple markers and spatial context is a promising but still emerging approach.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Taube, Janis M — Johns Hopkins University
- Study coordinator: Taube, Janis M
Related research
Other NIH-funded projects on the same topics.
-
Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer
This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.
-
Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype
A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.
-
Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging
A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.
-
ATM kinase as a target to help NSCLC with brain metastases respond to treatment
A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.
-
Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies
A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.
-
Delta immune ecology of NSCLC in KRAS-mutant cancers
A study in people with NSCLC (especially KRAS-mutant) will examine how immune cells and tumor interactions change during treatment and how this could guide better therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.